Patents
US 12414985 B2: Augmented acid alpha-glucosidase for the treatment of Pompe disease
- Granted
- 2025-09-16
- Filed
- 2022-03-21 application 17699927
- Type
- Utility · 33 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
A method for treating Pompe disease including administration of recombinant human acid α-glucosidase having optimal glycosylation with mannose-6-phosphate residues in combination with an amount of miglustat effective to maximize tissue uptake of recombinant human acid α-glucosidase while minimizing inhibition of the enzymatic activity of the recombinant human acid α-glucosidase is provided.
Source: PVGPATDIS, file of 2026-04-10 (ipg250916.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Amicus Therapeutics, Inc. 158 patents | US company or organization | Philadelphia, PA | AMICUS THERAPEUTICS, INC. Form D issuer EXACT high confidence: identical full name and state AMICUS THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Hung V. Do | New Hope, PA | 33 | PVGPATDIS, file of 2026-04-10 | |
| Richie Khanna | Raritan, NJ | 14 | PVGPATDIS, file of 2026-04-10 | |
| Russell Gotschall | Doylestown, PA | 17 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K38/47 | PVGPATDIS, file of 2026-04-10 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P3/00 | PVGPATDIS, file of 2026-04-10 |
| C12Y | Enzymes | C12Y302/0102 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2026-04-27 | Release of security interest Release of security interest | WILMINGTON TRUST, NATIONAL ASSOCIATION signed 2026-04-27 | AMICUS THERAPEUTICS, INC. PHILADELPHIA, PA | 75494/30 | PASDL, file of 2026-08-13 |
| 2026-04-27 | Security interest Security interest Security interest | BIOMARIN PHARMACEUTICAL INC. signed 2026-04-27 AMICUS THERAPEUTICS, INC. signed 2026-04-27 | CITIBANK, N.A., AS COLLATERAL AGENT NEW YORK, NY | 75493/968 | PASDL, file of 2026-10-15 |
| 2023-10-06 | Security interest Security interest Security interest | AMICUS THERAPEUTICS, INC. signed 2023-10-05 | WILMINGTON TRUST, NATIONAL ASSOCIATION MINNEAPOLIS, MN | 65177/196 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.